C
Claire N. Harrison
Researcher at Guy's and St Thomas' NHS Foundation Trust
Publications - 511
Citations - 24605
Claire N. Harrison is an academic researcher from Guy's and St Thomas' NHS Foundation Trust. The author has contributed to research in topics: Ruxolitinib & Myelofibrosis. The author has an hindex of 66, co-authored 424 publications receiving 19843 citations. Previous affiliations of Claire N. Harrison include St Thomas' Hospital & National Health Service.
Papers
More filters
P991: impairment of tcr signalling in patients with myelofibrosis treated with ruxolitinib
P. Harrington,Richard Dillon,Deepti Radia,Donal P. McLornan,Natalia Curto-Garcia,Claire Woodley,S. Asirvatham,Shahram Kordasti,Claire N. Harrison,Hugues de Lavallade +9 more
TL;DR: Studies have shown that rux inhibits T cell proliferation and reduces CD4+ cell cytokine secretion, suggesting off target kinase inhibition is implicated in the impairment of TCR signalling.
Journal ArticleDOI
A discussion of blood cancers and the MPN landmark survey.
TL;DR: Professor Claire Harrison speaks to Roshaine Wijayatunga, managing commissioning editor: Professor Claire Harrison became a consultant at Guy's and St Thomas' hospital in 2001 and is an internationally regarded expert in her field as a patient advocate.
Journal ArticleDOI
3170 – single-cell multi-omics resolves the evolution of tp53-mutant leukemia
Alba Rodriguez-Meira,Ruggiero Norfo,Wei Wen,Agathe L. Chédeville,Haseeb Rahman,Jennifer O'Sullivan,Guanlin Wang,E Louka,Warren W. Kretzschmar,A. Paterson,Charlotte K. Brierley,Caroline Demeule,Matthew Bashton,Nikolaos Sousos,Angela Hamblin,Hélène Guermouche,Florence Pasquier,Christophe Marzac,François Girodon,Mark Drummond,Claire N. Harrison,Isabelle Plo,Sten Eirik W. Jacobsen,Bethan Psaila,Supat Thongjuea,Iléana Antony-Debré,Adam J. Mead +26 more
TL;DR: In this article , a target-seq single-cell multi-omic analysis of haematopoietic stem/progenitor cells (HSPC) from patients with a myeloproliferative neoplasm who had transformed to TP53-mutant secondary acute myeloid leukaemia (sAML) was carried out.
Journal ArticleDOI
Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis – an option beyond ruxolitinib
Chandan Saha,Claire N. Harrison +1 more
TL;DR: Fedratinib presents a much needed option of treatment, particularly, for patients failing Ruxolitinib, with response rates that are quite similar, Nonetheless, there remain important questions including sequencing and options for combining therapy.
Journal ArticleDOI
Considerations to comprehensive care for the older individual with myelofibrosis.
TL;DR: In this paper , a review of available data addressing the issues of myelofibrosis in older individuals is presented, outlining knowledge gaps and suggesting a summative and holistic approach to the older individual with myeloffibrosis.